Real-world characteristics of elderly patients with overactive bladder in the United States

Abstract

Elderly patients with OAB in the general population have high levels of functional impairment and physical limitations, comorbidity, and concomitant medication use. These characteristics should be taken into consideration when managing OAB symptoms and designing future clinical studies. These results, which are representative of elderly patients with OAB in the general US population, should, however, be interpreted in light of the key limitations of the data we used: patients may have been misclassified and medical conditions overestimated due to artifacts of diagnosis coding and our results can only be generalized to patients who were enrolled in Medicare Parts A, B, and D for at least 12 continuous months.

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

“…Patients in this study were community dwelling and relatively healthy, as shown by low baseline Charlson Comorbidity Index scores. However, the number of concomitant medications and comorbid conditions observed at baseline in this study are similar to those in the general older population [8].…”

“…By 2025, it is estimated that there will be 52 million adults in the USA with LUTS [5]. The older patient population with OAB has high levels of concomitant medication use and comorbidity, is more likely to experience falls and fractures, and is at increased risk of impairment of activities of daily living [6][7][8]. However, frail elderly patients with multiple comorbidities are often excluded from clinical trials [9][10][11].…”

Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension

“…Based on Medicare claims and Medicare Current Beneficiary Surveys from 2006 to 2011 in the USA, the mean age of elderly patients with OAB (78.5 years) was greater than that of patients without OAB (76.9 years), and patients with OAB were more likely to be aged ≥75 years (65.4%) than those without OAB (53.9%) . The rate of elderly (aged ≥65 years) women patients who were prescribed OAB treatment medicines was 84.2%, and the rate of those aged ≥75 years was 63.0% in Japan .…”

“…HT, diabetes, hyperlipidemia and nicotine abuse) might play a role in the development of LUTS. In the USA, elderly patients with OAB had higher rates of comorbid HT, hyperlipidemia and diabetes mellitus than patients without OAB . For example, 57.9% of elderly patients with OAB had comorbid HT versus 43.5% of those without OAB .…”

“…9 For example, 57.9% of elderly patients with OAB had comorbid HT versus 43.5% of those without OAB. 9 Women might be more sensitive than men to vascular risk factors. In Japan, the percentage of elderly women with OAB who were co-prescribed an antihypertensive drug was 60.0%.…”